anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An epiretinal membrane (ERM) is a frequently occurring disease affecting the macula, which can be associated with visual impairment and metamorphopsia, depending on the severity and location. A distinction is made between an idiopathic form caused by age-related changes of the vitreous body and a secondary form associated with diseases of the posterior segment. The development of fibrocellular epiretinal membranes formed by dedifferentiation of intraretinal and extraretinal cells at the level of the vitreomacular interface plays a major role in the pathogenesis. The diagnostics and indications for surgical treatment of ERM are based on the visual acuity, evidence of metamorphopsia, ophthalmoscopic findings and optical coherence tomography (OCT) of the macula. In addition to the possibility of observation of the course where benign spontaneous courses are not uncommon, pars plana vitrectomy (PPV) with peeling of the ERM and internal limiting membrane (ILM) to prevent recurrences is the treatment of choice in symptomatic patients. The prognosis after surgical treatment is very good. In approximately two thirds of the cases, an improvement in visual acuity and/or a reduction of metamorphopsia can be achieved, with a number of predictive, primarily OCT-based factors enabling a prediction of the functional prognosis. Comprehensive patient education regarding the generally long duration of postoperative rehabilitation and the possibility of persistent symptoms or visual deterioration despite successful membrane removal is essential.
Patients receive HiDAC IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats no earlier than 28 days after the prior course and no later than 14 days after hematopoietic recovery for two more courses.
Ice pack applied to the abdomen and maintained continuously for the first 12 hours post-operatively. Standard standard post-operative analgesia orders will be followed in addition to use of ice.
BACKGROUND: Modular connections in total hip arthroplasty (THA) offer surgical advantages, but can contribute to implant fretting and corrosion due to micromotion at the head-stem interface. Previous studies implicated lower flexural rigidity as a key contributing factor to THA corrosion and fretting, but none associated flexural rigidity with direct histological evaluation or magnetic resonance imaging (MRI) outcomes. The purpose of this study was to determine how implant flexural rigidity is associated with MRI imaging metrics and histopathological outcomes in patients who have a failed THA.
METHODS: Patients requiring revision THA surgery underwent preoperative MRIs with 3-dimensional multispectral imaging techniques to suppress metal artifacts. The MRI images were graded for adverse local tissue reactions. For each hip, trunnion flexural rigidity was measured from the retrieved femoral stem, and a periprosthetic tissue sample was retrieved and evaluated using semiquantitative histology. Generalized linear models and analyses of variance were used to assess associations between flexural rigidity and MRI and histology outcomes.
RESULTS: A total of 106 THA stems were retrieved (46 women and 60 men, age: 68 years (range, 60 to 73 years). After adjustment for length of implantation, flexural rigidity was negatively correlated with histologic aseptic lymphocyte-dominant vasculitis-associated lesion severity (β = -26.27, P = .018), Fujishiro lymphocyte grading (β = -13.4, P = .039), perivascular lymphocyte layers (β = -17.8, P = .022), the grade of tissue organization (β = -22.5, P = .009), the presence of diffuse synovitis (β = -66.5, P = .003), and the presence of lymphoid aggregates (β = -75.9, P = .022). No association was found between MRI metrics and flexural rigidity.
CONCLUSIONS: Among these implants, decreased trunnion stiffness was associated with increased histologic features of adverse host-mediated soft tissue reactions.
PURPOSE:A liver-spot improver, containing the terrestrial part of leaves or stems of honewort or parsley as an essential component, produced from a very highly safe vegetable used as food for a long time as a raw material and useful for food, cosmetic, etc. CONSTITUTION:A liver-spot improver containing an extract, obtained by extracting dried powder of the terrestrial part of annual or biennial herb umbelliferous honewort and/or parsley which are edible plants or a readily metabolizable extract obtained by extracting the terrestrial part with an aqueous solvent, e.g. water, physiological saline or dilute aqueous organic acid, which is a solvent containing at least >=95wt% water as an essential component. The above-mentioned improver is formulated into a food form, e.g. tea, refreshing drink, pill, powder, confectionery, bread, cookie or curry, etc., as an internal improving method or into a cosmetic, e.g. toilet water, pack, face washing water or soap, etc. The above-mentioned essential component may be eaten in 500-10,000mg/adult/day expressed in terms of dry raw material. EFFECT:The peroxylipid value of user's epidermis on trial is being normalized and this improver is considered as useful for cosmetic dermatitis, pimples, etc.
The invention discloses an application of black corn polysaccharide in preparing a medicament for preventing or treating senile osteoporosis. The evaluation of the prevention or treatment effect of the black corn polysaccharide on senile osteoporosis comprises the improvement effect on serum bone metabolic markers, bone microstructures and bone biomechanics. The black corn polysaccharide of the invention is deproteinized from dry black corn grains by water extraction and alcohol precipitation and Sevag method, H  2  O  2  Depigmenting by a method, and dialyzing by a dialysis bag to obtain polysaccharide powder. The black corn polysaccharide has an improvement effect on unbalance of serum bone metabolic markers of senile osteoporosis, deterioration of bone microstructure and reduction of bone strength. The results show that inIn the aspect of preventing senile osteoporosis, the black corn polysaccharide has great improvement effect on bone loss. Therefore, the black corn polysaccharide has important significance in developing senile osteoporosis clinically.
The primary purpose of the proposed study is to examine the effect of a home-based physical activity variety intervention on objectively measured physical activity in an eight-week randomized intervention trial. Early research on physical activity variety has observed increased physical activity participation, motivation, and enjoyment as a result of physical activity variety. However, previous studies examining variety have not included home-based interventions, objective measures of physical activity, or cardiovascular fitness classes.

Forty low-active college students will be randomly assigned to either an eight-week physical activity variety intervention (n=20) or a physical activity consistency comparison condition (n=20). Physical activity will be assessed via an accelerometer (e.g., Actigraph) at baseline and eight weeks, and psychosocial variables at baseline, four weeks, and eight weeks (i.e., post-intervention). Affect will be assessed at one, four, and eight weeks. Participants will receive counseling sessions and access to a website containing workouts appropriate to their condition.
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition. See Figure 10. WO 2005/099701 PCT/US2005/012427 35- Treatment means over time ** -0- Placebo (N=47) --- Farrpridine Responders (N=58) -10 titration 1st stable 2nd stable 3rd stable *: Significantly better than placebo and fampridine non-responders (p <0.001 for each). *: Significantly better than fampridine non-responders. Fig. 10
The use of sumatriptan nasal spray is contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of sumatriptan nasal spray. Some of these reactions occurred in patients without known CAD. Sumatriptan nasal spray may cause coronary artery vasospasm (Prinzmetal's angina), even in patients without a history of CAD.

Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving sumatriptan nasal spray. If there is evidence of CAD or coronary artery vasospasm, sumatriptan nasal spray is contraindicated. For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider administering the first dose of sumatriptan nasal spray in a medically supervised setting and performing an electrocardiogram (ECG) immediately following administration of sumatriptan nasal spray. For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of sumatriptan nasal spray.
<P>PROBLEM TO BE SOLVED: To provide a simple method for manufacturing perfume with reduced cost, remarkably shortening time for development of the perfume.  <P>SOLUTION: The method for manufacturing perfume includes a step of preparing diluted solutions of a plurality of perfumes by diluting with organic solvents. The diluted solutions prepared are subjected to a pressurization treatment. The pressurization treatment is preferably carried out under a pressure of 200-1,000 MPa. The perfume emitting fragrance similar to that of a perfume having been subjected to a natural aging for some months is prepared by preserving the pressurized state for some hours.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Participants receive placebo for pembrolizumab IV on Day 1 of each 3-week cycle (Q3W) for 5 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 15 cycles. During the Q3W dosing period of placebo, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m\^2 IV once per week (QW) for 5 or 6 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80 Gray Units (Gy) for volume-directed and 75 Gy for point-directed given with the total duration of radiation treatment not to exceed 50 days (with an extension to a maximum of 56 days for unforeseen delays).
PROBLEM TO BE SOLVED: To obtain a water-in-oil type emulsion cosmetic excellent in emulsion stability, having a refreshing and good feeling in use. SOLUTION: This water-in-oil type emulsion cosmetic comprises (A) 0.5-20wt.% of a lactate, (B) 0.5-5wt.% of a melanin production nonionic surfactant (e.g. diglyceryl monoisostearate) liquid at a normal temperature, (C) 15-35wt.% of an oily component (e.g. squalane) and (D) water. The whole amount of the component A is dissolved in a part of water. A mixture of the solution and the component B is prepared, mixed with the component C and the rest of water and emulsified to prepare the objective water-in-oil type emulsion cosmetic. The cosmetic is properly mixed with a well-known component as necessary. When the cosmetic is used as an anti-suntan cosmetic, the cosmetic is mixed with 0.1-30wt.% of an anti-suntan component except an oily ultraviolet light absorber.  An emollient cream, hand cream, cleansing cream, foundation, make-up foundation cream, pack, milky lotion, etc., can be prepared besides the anti-suntan cosmetic.
Patients diagnosed with MS requiring urodynamic assessment will be recruited during outpatient visits at Toulouse University Hospital. Initial consultations will involve questionnaire completion, 72-hour voiding diaries, and urine sample collection just before urodynamic assessments.
1456775 Intrauterine device APAMED ANSTALT 4 Nov 1974 [9 Nov 1973] 47546/74 Headings A5B and A5R An intrauterine device consists of a hydrophobic substrate having a resilient memory, the substrate comprising wtihin its volume inclusions of a polymerised hydrophilic substance, grafted on to the substrate and cross-linked, in which are stored one or more water-soluble therapeutic or contraceptive agent(s) or agent(s) for acclimatizing the intrauterine device within the uterus, the agent(s) being such that they perfuse through the hydrophobic substrate when the device is placed in an aqueous medium. Fig. 7 shows such a device consisting of two thin sheets welded to a frame having a resilient memory, the thin sheets comprising hydrophilic inclusions and including between them therapeutic and/or contraceptive and/or acclimatizing agents which perfuse through the sheets when the device is placed in the uterus. The hydrophobic substrate may be composed of polyvinyl acetate, polyethylene or a co-polymer of ethylene and vinyl acetate, a polyethylene copolymer, a polyether, a polyurethane, a polyacrylonitrile, polypropylene, a polyamide, polyvinyl chloride, polyformaldehyde chloride, polycarbonates, polytetrafluoroethylene or polyesters. The hydrophilic substance may be chosen from polymers, or co-polymers with the hydrophobic substrate of ethylene glycol acrylate, ethylene glycol methacrylate, acrylamide, methacrylamide, acrylamide methylol or acrylamide diacetone, or an unsaturated carboxylic acid, propylene glycol acrylate or methacrylate. The active agents stored in the device may be vitamins, amino-caproic acid, ergotamine, ergotimine, diosmin, iron sulphate, calcium salts, copper, zinc, cobalt, lead or cadmium salts, progesterone, spermicides, oestrogens or antibiotics.
The NHLBI Stem Cell Allotransplantation Program is researching methods to improve allogeneic stem cell transplantation. We are particularly interested in identifying factors, which result in individual variability in outcomes. Cytokines are biological modulators of the immune system known to influence various phases of the immune response. Normal variations in the genetic material coding for cytokines (Cytokine Gene Polymorphisms or CGPs) are believed to account for some of the differences in the inflammatory response between individuals. In the future, we hope to tailor stem cell transplantation to take into account these immunological profiles. In order to characterize the effect of any such intervention, we first need to better understand the role CGPs play in immune responses in normal, healthy persons. This involves testing for the presence or absence of a polymorphism in healthy individuals, and comparing with a validated in vitro assay. None of these polymorphisms are associated with known clinical disease to be classifiable as a 'genetic defect'. Moreover, we will not correlate these polymorphisms with clinical studies to identify traits in the sample donors. We plan to utilize stored blood samples from stem cell transplant donors who have previously participated on a hematology branch protocol as well as consent future donors.
The invention provides a chitosan microsphere. The chitosan microsphere comprises, by mass, 25-99% of chitosan and 1-75% of a hydrophilic polymer, and the hydrophilic polymer comprises at least one of polyvinyl alcohol, gelatin, cellulose and polyoxyethylene. The chitosan microsphere improves the moisture absorption capability and the moisture retention capability of chitosan, and solves the problem of traditional powder hemostasis materials. The invention also provides a preparation method of the chitosan microsphere. The method comprises the following steps: mixing a chitosan solution with a hydrophilic polymer solution until the chitosan solution and the hydrophilic polymer solution are uniform in order to prepare a mixed solution; and adding the mixed solution to a negatively charged receiving solution in a dropwise manner through adopting an electrostatic spraying technology, standing to obtain a microsphere suspension, separating to obtain microspheres, washing the microspheres, and drying the washed microspheres to obtain the chitosan microsphere. The preparation method has the advantages of simplicity and mild conditions, and the dimensions of the prepared chitosan microsphere are uniform and controllable.
In the intervention group, the researcher gave feedback on the subjects' exercise amount through telephone contact every 2 weeks during the 12-week study period. Through phone consultations, they answered questions about exercise or discussed problems, encouraged to continue exercising, answered questions or discussed problems related to wearable devices and apps, and encouraged continuous data transmission.
Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
Patients will receive an injection of up to 7.5 (0.5-7.5) mCi of \[18F\]-SKI- 249380, followed by serial PET/CT scanning and blood draws, over a period of 3.5 hours, on a single day. PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. Each patient will be offered the opportunity to repeat the 18F-SKI-249380 injection and subsequent set of post-injection PET-CT scans, once, on a separate date. Each patient may or may not be receiving treatment with dasatinib therapy at the time of 18F-SKI-249380 PET, for their first PET study, as well as repeat PET study, at the discretion of their oncologist according to best clinical judgment.
Background: Aging is a natural biological process influenced by multiple factors and is a significant contributor to various chronic diseases. Slowing down the aging process and extending health span have been pursuits of the scientific field. Methods: Examination of the effects of dietary polyphenols on hallmarks of aging such as genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis. Results: Polyphenols, abundant in nature, exhibit numerous biological activities, including antioxidant effects, free radical scavenging, neuroprotection, and anti-aging properties. These compounds are generally safe and effective in potentially slowing aging and preventing age-related disorders. Conclusions: The review encourages the development of novel therapeutic strategies using dietary polyphenols to create holistic anti-aging therapies and nutritional supplements.
Traumatic brain injury (TBI) is a major cause of morbidity and mortality in children. Most children with moderate and severe TBI have long term sequelae including neurological deficit, cognitive impairment and behavioural disorders. In the acute care setting, neither clinicians nor researchers are able to adequately predict the long term outcome of children with TBI, consequently limiting their ability to tailor medical care, rehabilitation and support services. Improving our understanding of a TBI patient's exact cerebral status and prognosis is a critical step toward optimized and personalized patient management. In this research study, an innovative and integrated model will be developed to improve the prognostication in the early phase of a TBI. This model will combine key clinical variables commonly collected in the acute care setting and combine these with cutting-edge empirical measures: 1) biomarkers; 2) a new physiological monitoring based on heart-rate variability (HRV) to assess the integrity of the autonomic system; and 3) a computerized classification tool developed using the concept of artificial intelligence to continuously categorize the patient's cerebral status.
BACKGROUND: Liver fibrosis typically develops as a result of chronic liver injury, which involves inflammatory and regenerative processes. The triggering receptor expressed on myeloid cells 2 (TREM2), predominantly expressing in hepatic non-parenchymal cells, plays a crucial role in regulating the function of macrophages. However, its mechanism in liver fibrosis remains poorly defined.
METHODS: Experimental liver fibrosis models in wild type and TREM2-/- mice, and in vitro studies with AML-12 cells and Raw264.7 cells were conducted. The expression of TREM2 and related molecular mechanism were evaluated by using samples from patients with liver fibrosis.
RESULTS: We demonstrated that TREM2 was upregulated in murine model with liver fibrosis. Mice lacking TREM2 exhibited reduced phagocytosis activity in macrophages following carbon tetrachloride (CCl4) intoxication. As a result, there was an increased accumulation of necrotic apoptotic hepatocytes. Additionally, TREM2 knockout aggravated the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from dead hepatocytes during CCl4 exposure, and further promoted the occurrence of macrophage-mediated M1 polarization. Then, TREM2-/- mice showed more serious fibrosis pathological changes. In vitro, the necrotic apoptosis inhibitor GSK872 effectively alleviated the release of mito-DAMPs in AML-12 cells after CCl4 intoxication, which confirmed that mito-DAMPs originated from dead liver cells. Moreover, direct stimulation of Raw264.7 cells by mito-DAMPs from liver tissue can induce intracellular inflammatory response. More importantly, TREM2 was elevated and inflammatory factors were markedly accumulated surrounding dead cells in the livers of human patients with liver fibrosis.
CONCLUSION: Our study highlights that TREM2 serves as a negative regulator of liver fibrosis, suggesting its potential as a novel therapeutic target.
Restless Legs Syndrome (RLS) is a sensory-motor neurological disorder characterized by an irresistible urge to move the legs. Persistent difficulties with all phases of sleep are common in patients whose RLS symptoms are resolved with treatment. Multiple potential causes for treatment-refractory sleep disturbance exist, including activating effects of dopamine agonists (which are first-line RLS treatments), conditioned insomnia and poor sleep habits as a result of chronic RLS-related sleep disturbance, and comorbid medical and psychiatric illness. Suvorexant provides an important therapeutic option to treat insomnia in the context of RLS. It has demonstrated long-term efficacy, particularly in shortening the duration of nocturnal awakenings and increasing total sleep time. Similarly, it has a comparatively benign side effect profile compared to many other agents typically prescribed to treat insomnia. The investigators aim to determine the effect of suvorexant on actigraphically-derived total sleep time, as well as actigraphically-derived wake after sleep onset, Insomnia Severity Index score, subjective sleep endpoints, and RLS symptom severity.
FIELD: medicine. SUBSTANCE: invention relates to the developed recombinant immunotoxin based on DIPHTHERITIC toxin and interleukin-2 where catalytic-transmembrane moiety of diphtheric toxin contains 482 amino acids. Invention proposes also a method of preparing recombinant immunotoxin DT482-IL2. New immunotoxin can be used for making drug used for treatment of tumor and autoimmune diseases. Method provides high protein toxicity and capability to secret into extracellular space. EFFECT: enhanced effectiveness and properties of immunotoxin. 2 cl, 3 dwg